SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001661539-23-000006
Filing Date
2023-10-06
Accepted
2023-10-06 17:21:38
Documents
3
Period of Report
2023-10-05

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1696627288.html 4  
1 FORM 4 wk-form4_1696627288.xml 4 3320
2 EX-24 a2023-05x24secpoajosetre.htm EX-24 644
3 GRAPHIC a2023-05x24secpoajosetre001.jpg GRAPHIC 218470
  Complete submission text file 0001661539-23-000006.txt   306394
Mailing Address C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618
Business Address
Trevejo Jose M. (Reporting) CIK: 0001661539 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39614 | Film No.: 231314962

Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Issuer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)